Pharmacokinetics of DOLUTEGRAVIR once daily and ELVITEGRAVIR/COBICISTAT once daily over 10 days following drug intake cessation in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
Indications HIV-1 infections
Focus Pharmacokinetics

03 Feb 2020 Results (N=93), analysis of the data pooled from 4 trials(3 phase I studies NCT02219217, NCT02509195 and NCT03094507 and one Phase III NCT02351908) assessing genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics, published in the Journal of Antimicrobial Chemotherapy
12 Aug 2016 Status changed from active, no longer recruiting to completed.
17 Dec 2015 Results published in the Journal of Antimicrobial Chemotherapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com